

AMERICAN SOCIETY OF GENE THERAPY

8th Annual Meeting
CALL for ABSTRACTS

Deadline for submission:
February 7, 2005

June 1-5, 2005
America's Center
St. Louis, Missouri

AMERICAN
SOCIETY of

 **GENE
THERAPY**

www.asgt.org

GENERAL MEETING INFORMATION

ASGT

The American Society of Gene Therapy is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene and related cell and nucleic acid therapies. ASGT was established in 1996, and has grown to close to 3,000 members from around the world. The goals of the Society are to:

- Promote Research, Development and Application
- Exchange Information and Promote Education
- Promote Development of Clinical Translations

The ASGT 8th Annual Meeting will serve as a comprehensive forum to achieve these goals.

MEETING DATES

The ASGT 8th Annual Meeting will take place June 1-5, 2005 in St. Louis, Missouri.

EDUCATIONAL OBJECTIVES

At the conclusion of the activity, the participant should be able to:

- Discuss some key aspects of the current laboratory and/or clinical research in gene therapy.
- Demonstrate knowledge of methods being used by gene therapy researchers and practitioners.
- Describe one or more stimulating new areas of inquiry in the area of gene therapy.
- Demonstrate familiarity with federal regulations and guidelines for clinical gene transfer studies.

TARGET AUDIENCE

The target audience includes basic science and translational researchers, clinical investigators, physicians, postdoctoral fellows, graduate students, employees of federal government and regulatory agencies, and other healthcare professionals with an interest in the latest advancements in the field of gene and related cell and nucleic acid therapies.

ACCREDITATION/CREDIT DESIGNATION

ASGT is applying for Category 1 CME credits for the 8th Annual Meeting.

SUBMISSION DEADLINE – February 7, 2005 at 4:00 pm EST.

Avoid delays by submitting early!

CALL FOR ABSTRACTS – GENERAL INFORMATION

Abstract receipt deadline for electronic submission: February 7, 2005 at 4:00 pm Eastern Standard Time.

ABSTRACT SUBMISSION PROCESS

ASGT will review all submitted abstracts and select abstracts for either oral or poster sessions. ASGT expects that all abstracts selected for presentation will be presented by the authors and that submitted abstracts will not be withdrawn. All accepted abstracts become the property of ASGT and will be published in *Molecular Therapy* and on the ASGT website. Please do not submit an abstract if you are not prepared to travel to the meeting and present it in the form selected by ASGT.

ELECTRONIC SUBMISSION

Please go directly to the ASGT website at www.asgt.org for complete instructions to begin the submission process. There is no fee for electronic abstract submissions.

ELIGIBILITY

Members of ASGT, as well as nonmembers, are eligible to submit abstracts. Submitting an abstract does not register you for the Annual Meeting. You must also register for the meeting. Meeting registration is available online at www.asgt.org.

PRIOR PUBLICATION

Papers that have been published prior to the time of presentation may not be submitted unless special consideration is requested. Special consideration may be requested by checking the appropriate box on the abstract form and providing a statement explaining the special circumstances.

REVIEW PROCESS

Abstracts will be peer-reviewed according to the subject category. Authors must indicate the review category (only one) during the electronic submission process. An abstract category must be selected before an abstract will be reviewed.

ABSTRACT PLACEMENT

The ASGT Program Committee will determine where abstracts will be placed within the program. All abstracts submitted will be considered for one presentation: either oral (simultaneous session) or poster.

TRAINEE TRAVEL GRANTS

ASGT will be offering a limited number of travel grants to postdoctoral fellows and students. The grants will be based on the highest abstract scores, as determined by the ASGT Abstract Review Committee.

The travel grants are worth up to \$500 for reimbursement for meeting-related expenses including lodging, travel and meals. **To be considered for such a grant, please make sure to check one of the two boxes for Trainee Travel Award Consideration.** Please note: Meeting registration fees are non-reimbursable; travel grant recipients must register for the meeting and pay the registration fees.



SIMULTANEOUS ORAL PRESENTATION SESSIONS

Simultaneous Oral Presentation Sessions are formal, LCD/PowerPoint presentations, followed by a brief discussion.

POSTER SESSIONS

Poster Sessions allow the review of an illustration of the abstract. At specific intervals, authors will be present to informally discuss their work. Authors are requested to post and remove posters at designated times.

NOTIFICATION

Notification regarding acceptance or rejection of abstracts will be made in mid-March 2005. Travel Grant and Outstanding Research Award acceptance and rejection letters will also be mailed at this time. If you have not received your notification by April 15, 2005, please contact: Ken Janowski, Program Manager

Phone: (414) 278-1341

Fax: (414) 276-3349

E-mail: info@asgt.org

ABSTRACT PUBLICATION

All abstracts accepted for presentation will be published in a supplement to *Molecular Therapy*, the Society's official journal. The abstract volume will be distributed at the ASGT 8th Annual Meeting in St. Louis. Abstracts will be available on the ASGT website at www.asgt.org beginning May 2, 2005.

ELECTRONIC SUBMISSION

Your abstract must be submitted on or before the deadline of 4:00 pm EST on February 7, 2005. Late abstracts will not be accepted. There is no fee to submit an abstract online. Go directly to www.asgt.org for complete instructions on submitting your abstract.

TOPIC CATEGORIES

Please select one topic from the list on the opposite side of this page that best describes your abstract. Category selection is mandatory to submitting abstracts. The online program will not accept an abstract unless a category is selected.

Work on vectors that illustrates basic principles of the vector system or is restricted to *in vitro* studies should be directed to categories A and B. Application of vectors in specific diseases or organ systems in animals or patients should be directed to category C.

SUBMISSION DEADLINE – February 7, 2005 at 4:00 pm EST.

Avoid delays by submitting early!

ABSTRACT CATEGORIES

VIRAL VECTOR DEVELOPMENT

Vectors not specifically mentioned should be directed to the most closely related category. Hybrid vectors should be directed to the category that makes the largest contribution to the performance of the vector system.

- A1. RNA Virus Vectors
- A2. AAV Vectors
- A3. Adenovirus Vectors
- A4. Other DNA Viruses

NONVIRAL VECTOR DEVELOPMENT

- B1. Naked DNA Gene Transfer
- B2. Lipid Mediated Gene Transfer
- B3. Molecular Conjugates

DISEASE MODELS AND CLINICAL APPLICATIONS

- C1. Inborn Errors of Metabolism – (includes hemophilia)
- C2. Cardiovascular
- C3. Neurologic – (includes inherited, progressive and acquired diseases)
- C4. Muscle and Connective Tissue – (includes inherited, progressive and acquired diseases)
- C5. Infectious Diseases and Vaccines
- C6. Cancer - Immunotherapy
- C7. Cancer - Apoptosis
- C8. Cancer - Suicide
- C9. Cancer – Targeted Gene Therapy
- C10. Hematologic – (excludes leukemia, lymphoma or hemophilia)
- C11. Lung and Respiratory Disease

GENE REGULATION

- D. Gene Regulation – (includes gene expression, animal model systems and gene modification)

ABSTRACT QUESTIONS

For questions regarding the abstract submission process, please contact Marathon Multimedia's Technical Support at: Phone: (507) 334-5212
E-mail: support@marathonmultimedia.com

Technical Support is open Monday – Friday during the following hours:
9:00 am – 6:00 pm Eastern Standard Time
8:00 am – 5:00 pm Central Standard Time
7:00 am – 4:00 pm Mountain Standard Time
6:00 am – 3:00 pm Pacific Standard Time